Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/FBLN1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/FBLN1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/FBLN1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/FBLN1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/FBLN1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/FBLN1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/FBLN1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/FBLN1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003444620 | Esophagus | ESCC | substrate adhesion-dependent cell spreading | 65/8552 | 108/18723 | 1.67e-03 | 7.72e-03 | 65 |
GO:00075668 | Esophagus | ESCC | embryo implantation | 35/8552 | 53/18723 | 2.22e-03 | 9.78e-03 | 35 |
GO:004586212 | Liver | Cirrhotic | positive regulation of proteolysis | 163/4634 | 372/18723 | 4.18e-16 | 5.14e-14 | 163 |
GO:005254712 | Liver | Cirrhotic | regulation of peptidase activity | 185/4634 | 461/18723 | 1.32e-13 | 1.09e-11 | 185 |
GO:002260412 | Liver | Cirrhotic | regulation of cell morphogenesis | 127/4634 | 309/18723 | 1.45e-10 | 7.44e-09 | 127 |
GO:004206012 | Liver | Cirrhotic | wound healing | 155/4634 | 422/18723 | 2.12e-08 | 7.56e-07 | 155 |
GO:00109527 | Liver | Cirrhotic | positive regulation of peptidase activity | 81/4634 | 197/18723 | 2.89e-07 | 7.03e-06 | 81 |
GO:001081012 | Liver | Cirrhotic | regulation of cell-substrate adhesion | 88/4634 | 221/18723 | 4.89e-07 | 1.10e-05 | 88 |
GO:004593612 | Liver | Cirrhotic | negative regulation of phosphate metabolic process | 154/4634 | 441/18723 | 8.78e-07 | 1.83e-05 | 154 |
GO:001056312 | Liver | Cirrhotic | negative regulation of phosphorus metabolic process | 154/4634 | 442/18723 | 1.02e-06 | 2.11e-05 | 154 |
GO:190002412 | Liver | Cirrhotic | regulation of substrate adhesion-dependent cell spreading | 31/4634 | 57/18723 | 1.55e-06 | 3.02e-05 | 31 |
GO:004232612 | Liver | Cirrhotic | negative regulation of phosphorylation | 135/4634 | 385/18723 | 3.17e-06 | 5.58e-05 | 135 |
GO:003158912 | Liver | Cirrhotic | cell-substrate adhesion | 128/4634 | 363/18723 | 4.10e-06 | 6.90e-05 | 128 |
GO:001076912 | Liver | Cirrhotic | regulation of cell morphogenesis involved in differentiation | 43/4634 | 96/18723 | 1.42e-05 | 1.97e-04 | 43 |
GO:003444612 | Liver | Cirrhotic | substrate adhesion-dependent cell spreading | 47/4634 | 108/18723 | 1.48e-05 | 2.05e-04 | 47 |
GO:000193312 | Liver | Cirrhotic | negative regulation of protein phosphorylation | 117/4634 | 342/18723 | 4.84e-05 | 5.59e-04 | 117 |
GO:000759611 | Liver | Cirrhotic | blood coagulation | 79/4634 | 217/18723 | 8.06e-05 | 8.81e-04 | 79 |
GO:000759911 | Liver | Cirrhotic | hemostasis | 80/4634 | 222/18723 | 1.08e-04 | 1.10e-03 | 80 |
GO:005081711 | Liver | Cirrhotic | coagulation | 79/4634 | 222/18723 | 1.90e-04 | 1.76e-03 | 79 |
GO:00723761 | Liver | Cirrhotic | protein activation cascade | 9/4634 | 12/18723 | 3.59e-04 | 3.03e-03 | 9 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FBLN1 | SNV | Missense_Mutation | rs752324735 | c.1679A>C | p.Tyr560Ser | p.Y560S | P23142 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A1FX-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD |
FBLN1 | SNV | Missense_Mutation | | c.1905C>A | p.Asp635Glu | p.D635E | P23142 | protein_coding | tolerated(0.17) | benign(0.081) | TCGA-D8-A147-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD |
FBLN1 | SNV | Missense_Mutation | | c.1679A>G | p.Tyr560Cys | p.Y560C | P23142 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
FBLN1 | SNV | Missense_Mutation | rs749073587 | c.482N>T | p.Thr161Met | p.T161M | P23142 | protein_coding | tolerated(0.13) | benign(0.003) | TCGA-E9-A22A-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
FBLN1 | insertion | Nonsense_Mutation | novel | c.751_752insCCAGATGTTAGATGTTTTATCTCTCCGTCTTTTATCT | p.Gly251AlafsTer4 | p.G251Afs*4 | P23142 | protein_coding | | | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | | SD |
FBLN1 | SNV | Missense_Mutation | novel | c.1027N>T | p.Arg343Cys | p.R343C | P23142 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
FBLN1 | SNV | Missense_Mutation | novel | c.1512N>A | p.Ser504Arg | p.S504R | P23142 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
FBLN1 | SNV | Missense_Mutation | | c.1788N>G | p.Ile596Met | p.I596M | P23142 | protein_coding | deleterious(0.02) | possibly_damaging(0.572) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
FBLN1 | SNV | Missense_Mutation | rs200901023 | c.1721C>T | p.Thr574Met | p.T574M | P23142 | protein_coding | tolerated(0.06) | probably_damaging(0.993) | TCGA-AA-3678-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | folinic | CR |
FBLN1 | SNV | Missense_Mutation | rs759317468 | c.826N>A | p.Asp276Asn | p.D276N | P23142 | protein_coding | tolerated(0.4) | benign(0.044) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |